Cita APA

Llibre, J. M., López Cortés, L. F., Aylott, A., Wynne, B., Matthews, J., Van Solingen-Ristea, R., . . . Kahl, L. P. (2022). Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2.

Citación estilo Chicago

Llibre, Josep M., Luis Fernando López Cortés, Alicia Aylott, Brian Wynne, Jessica Matthews, Rodica Van Solingen-Ristea, Kati Vandermeulen, Jean van Wyk, y Lesley P. Kahl. Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2. 2022.

Cita MLA

Llibre, Josep M., et al. Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2. 2022.